RxDoctor Payments DataLook up a doctor →

Edward Washabaugh, MD

Interventional Pain Medicine · Ann Arbor, MINPI 1952409344

Payments from drug & device makers

$559,078in general payments, 2019–2025

Across 530 payments — averaging $1054.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$412K
  • Vertos Medical, Inc.$121K
  • Nevro Corp.$14K
  • Stryker$4K
  • Medtronic$1K
  • Globus Medical$1K
  • plus $5K from 20 others
$2,794in research payments, 2019–2025

Across 2 payments — averaging $1397.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Nevro Corp.$3K

What the payments were for

  • Travel & lodging$2,91829%
  • Food & beverage$7,28171%
  • Education$110%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$559,078 in reported general payments places this provider in the 95th percentile of 88 interventional pain medicine providers in Michigan.

See all interventional pain medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$341,178
Medicare patients
284
Services billed
37,951

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Buprenorphine35$7,533
LyricaPregabalin11$6,254
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen109$1,172
Gabapentin81$1,168
Morphine Sulfate ErMorphine Sulfate23$762
Oxycodone Hcl33$743
Tramadol Hcl ErTramadol Hcl13$737
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen41$558
Tizanidine Hcl24$477
Pregabalin21$450
Doxycycline Monohydrate22$312
Tramadol Hcl36$239
Cephalexin52$198
Hydromorphone Hcl23$187
Cyclobenzaprine Hcl12$129

Paid to pharmacies, not to this prescriber.

Other interventional pain medicine in Ann Arbor

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →